Founded in March 2025, RegenCell Global Corp. emerged from a vision to bridge the gap between groundbreaking stem cell technologies and those who can benefit from them. With decades of combined experience in the healthcare and biotech industries, our team saw the potential of stem cell therapies in regenerative medicine and wellness. As the industry grows and more clinics, hospitals, and research institutions seek reliable sources of stem cell products, we aim to be their trusted partner. By ensuring that every product we distribute meets the highest standards of quality, safety, and compliance, we are proud to be a leader in the evolving field of stem cell therapies. We supply the world with high-quality stem cells that support life-changing innovation.
We work with certified laboratories and adhere to strict quality standards to ensure every product is ethically sourced, thoroughly tested, and ready for clinical or research. We believe in the future of regenerative therapies. Our mission is to empower research and clinical innovations by providing top-tier, ethically acquired stem cell products.
Mission
To provide healthcare professionals with top-tier stem cell products, enabling them to offer innovative regenerative therapies and cosmetic solutions that improve patients’ lives
Vision
To become the most trusted distributor of stem cell therapies globally, helping to make regenerative treatments accessible to clinics, hospitals, and research institutions while adhering to the highest standards of safety and compliance.
Our Team
RegenCell Global’s executive management are:
- Mr. Calvin Cao – Chaiman & CEO
Mr. Calvin Cao is a founder of RegenCell Global Corp. As an inventor, innovator and Bio-Entrepreneur, his strategy and commitment to make RegenCell Global the dominant global company on the market for the entire field of cell therapy. In 2008, as a chairman and co-founder of Stem Cell Therapy International Corp. He engineered the merger of Stem Cell Therapy International and Histostem of South Korea. Histostem, one of the largest fully accredited cord blood banks in the world, with more than 80,000 cord blood units for use in research and treatments. The successful merger has formed one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity Amstem Corp.
- Dr. Dat Nguyen – President & CEO
He graduated his doctorate of Medicine in France – Faculté de Médecine Paris-Descartes. He is obtained his PhD of Science Economics and his MBA of Strategy & Management. He was a financial manager and businessman working in the banking and financial domain for more than 30 years. There was also high level advisor-consultant in the banking and financial institutions, on the strategy, the change and the commercial development.